stock
LXEO · Lexeo Therapeutics, Inc.
What Lexeo Therapeutics, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live LXEO price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on LXEO.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 82,046,255 as of 2026-08-10 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- -37.1%
- ROA
- -34.3%
Health
- Current ratio
- 13.9x
- Debt/equity
- —
Deep value
- NCAV
- $198.07M
- NCAV per share
- $2.41
- Price/NCAV
- Locked
- NNWC
- $73.00M
- NNWC per share
- $0.89
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | — | —Gross profit: unreported by this company. | -$28.02M | -$25.87M | 10-Q filed 2026-08-12 |
| 2026-03-31 | — | —Gross profit: unreported by this company. | -$22.33M | -$20.20M | 10-Q filed 2026-08-12 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-12-31 | — | —Gross profit: unreported by this company. | -$23.12M | -$20.96M | 10-Q filed 2026-08-12 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | — | —Gross profit: unreported by this company. | -$21.65M | -$20.28M | 10-Q filed 2025-11-05 |
| 2025-06-30 | — | —Gross profit: unreported by this company. | -$30.69M | -$26.10M | 10-Q filed 2026-08-12 |
| 2025-03-31 | — | —Gross profit: unreported by this company. | -$33.80M | -$32.66M | 10-Q filed 2026-08-12 Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-12-31 | — | —Gross profit: unreported by this company. | -$27.38M | -$25.92M | 10-K filed 2026-03-30 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| 2024-09-30 | — | —Gross profit: unreported by this company. | -$31.54M | -$29.49M | 10-Q filed 2025-11-05 |
- Assets
- $254.90M
- Equity
- $235.06M
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | — | -$109.26M | -$100.00M | -$98.96M |
| 2024-12-31 | — | -$105.77M | -$98.33M | -$81.63M |
| 2023-12-31 | — | -$68.51M | -$66.39M | -$59.61M |
| 2022-12-31 | $654,000 | -$60.51M | -$59.28M | -$55.23M |
Company filings
since Wed Nov 5 · 3 offering filings in 12 months · since Fri Oct 17
events
Acquisition or sale completed, Unregistered share sale
Acquisition or sale completedUnregistered share saleSep 298-KMaterial agreement, Other event
Material agreementOther eventSep 228-KResults, Other event
ResultsOther eventAug 128-KShareholder vote results
Shareholder vote resultsJun 298-KRegulation FD disclosure, Other event
Regulation FD disclosureOther eventJun 158-KResults, Other event
ResultsOther eventMay 118-K
5% owners ()
OrbiMed Advisors LLC
Passive stake
Paradigm BioCapital Advisors LP
Stake update
BALYASNY ASSET MANAGEMENT L.P.
Stake update
Affinity Asset Advisors, LLC
Stake update
STATE STREET CORPORATION
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
Tamayo Louis Edward
Chief Financial Officer
Sale$20,203Aug 19, 5:00 PM ET
Townsend Richard Nolan
Chief Executive Officer, Director
Sale$16,562Aug 19, 5:00 PM ET
Otero Jose Manuel
Chief Operating Officer
Sale$6,464Aug 19, 5:00 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
News
Stories that named LXEO, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about LXEO.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on LXEO come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the LXEO board